

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
27 March 2025 (27.03.2025)



(10) International Publication Number
WO 2025/064695 A1

(51) International Patent Classification:

A61K 9/08 (2006.01) *A61K 38/26* (2006.01)
A61K 47/26 (2006.01) *A61P 3/04* (2006.01)
A61K 38/28 (2006.01) *A61P 3/10* (2006.01)

(21) International Application Number:

PCT/US2024/047517

(22) International Filing Date:

19 September 2024 (19.09.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/539,788	21 September 2023 (21.09.2023)	US
63/613,443	21 December 2023 (21.12.2023)	US
63/662,263	20 June 2024 (20.06.2024)	US
63/673,012	18 July 2024 (18.07.2024)	US


(71) Applicant: **VILLYA LLC** [US/US]; 6300 N. Wickham Rd., Suite 130#194, Melbourne, Florida 32940 (US).

(72) Inventor: **MILLER, William Lee**; 537 Southern Hills Ct., Melbourne, Florida 32940 (US).

(74) Agent: **MEYER, Mercedes et al.**; BANNER & WITCOFF, Ltd., 1100 13th Street, N.W., Suite 1200, Washington, District of Columbia 20005 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: COMPOSITIONS AND METHODS FOR IMPROVING THE SOLUBILITY OF INSULIN, INSULIN ANALOGS, AND A1C OR GLUCOSE REGULATORY COMPOUNDS



(57) Abstract: A method is disclosed for improving the solubility of a drug compound, wherein the drug compound is insulin, a natural insulin variant, an insulin variant, or insulin analog, a GLP-I agonist, a GIP agonist, a glucagon agonist, an amylin agonist, or an incretin mimetic. The method uses a non-nutritive sugar such as rubusoside, rebaudioside A, dulcoside B, dodecyl- β -D-maltoside (DDM), or stevioside, or any combination thereof in the presence of a solvent such as ethanol or solvent mixtures thereof, and then removing the solvent by drying and solubilizing again to create a water-soluble complex that dissolves in water. Also described are complexes formed using the disclosed methods.

[Continued on next page]

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*